GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
G

Guangzhou Innogen Pharmaceutical Group Co 2591.HK · HKD

N/A · HKEX · 🇭🇰 Hong Kong

Compare

3.68

+1.66%

Close of 9 Nov 2026, in HKD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Guangzhou Innogen Pharmaceutical Group Co

Its shares trade on HKEX under the ticker 2591.HK. It has been listed since 15 August 2025. In the fiscal year to 31 December 2025, it reported revenue of CN¥149.2m and a net loss of CN¥387.3m. At that date it held total assets of CN¥1.83bn and shareholders' equity of CN¥1.23bn.

Guangzhou Innogen Pharmaceutical Group Co Ltd is a CN-based company operating in industry. The company is headquartered in Guangzhou, Guangdong. The company went IPO on 2025-08-15. Guangzhou Innogen Pharmaceutical Group Co Ltd is a China-based investment holding company principally engaged in the research, development and commercialisation of pharmaceutical products. The firm is primarily engaged in the commercialization of innovative, humanized, long-acting glucagon-like peptide-1 (GLP-1) receptor agonist. The firm is dedicated to developing therapies for diabetes and other metabolic diseases. The Company’s core product, Efsubaglutide Alfa (brand name: Diabegone), is used for the treatment of type 2 diabetes (T2D). The Company’s primary pipeline drug candidates include YN014, YN401, YN209, YN203, and YN202. The firm principally conducts its businesses in the domestic market.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
N/A
Industry
N/A
Listed since
15 Aug 2025

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Guangzhou Innogen Pharmaceutical Group Co Ltd focuses on innovative GLP-1 receptor agonist development for diabetes treatment.
  • Efsubaglutide Alfa (Diabegone) is a core product for type 2 diabetes management.
  • The company's primary pipeline includes YN014, YN401, YN209, YN203, and YN202 drugs.

Weaknesses

  • The company operates solely in the domestic market without international expansion.
  • Guangzhou Innogen Pharmaceutical Group Co Ltd has no international presence beyond China.
  • The firm's business is limited to the domestic market in Guangdong province.

Opportunities

  • The growing diabetes market in China offers significant expansion potential.
  • Efsubaglutide Alfa (Diabegone) can target the increasing T2D patient population.
  • The domestic market in Guangdong province provides a stable base for growth.

Threats

  • Competition from other Chinese pharmaceutical companies in the GLP-1 market.
  • Regulatory changes in China's pharmaceutical industry could impact operations.
  • Dependence on the domestic market may limit growth opportunities.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.